Norfluoxetine inhibits TREK-2 K2P channels by multiple mechanisms including state-independent effects on the selectivity filter gate.


Journal

The Journal of general physiology
ISSN: 1540-7748
Titre abrégé: J Gen Physiol
Pays: United States
ID NLM: 2985110R

Informations de publication

Date de publication:
02 08 2021
Historique:
received: 30 10 2020
accepted: 06 05 2021
entrez: 25 5 2021
pubmed: 26 5 2021
medline: 16 10 2021
Statut: ppublish

Résumé

The TREK subfamily of two-pore domain K+ (K2P) channels are inhibited by fluoxetine and its metabolite, norfluoxetine (NFx). Although not the principal targets of this antidepressant, TREK channel inhibition by NFx has provided important insights into the conformational changes associated with channel gating and highlighted the role of the selectivity filter in this process. However, despite the availability of TREK-2 crystal structures with NFx bound, the precise mechanisms underlying NFx inhibition remain elusive. NFx has previously been proposed to be a state-dependent inhibitor, but its binding site suggests many possible ways in which this positively charged drug might inhibit channel activity. Here we show that NFx exerts multiple effects on single-channel behavior that influence both the open and closed states of the channel and that the channel can become highly activated by 2-APB while remaining in the down conformation. We also show that the inhibitory effects of NFx are unrelated to its positive charge but can be influenced by agonists which alter filter stability, such as ML335, as well as by an intrinsic voltage-dependent gating process within the filter. NFx therefore not only inhibits channel activity by altering the equilibrium between up and down conformations but also can directly influence filter gating. These results provide further insight into the complex allosteric mechanisms that modulate filter gating in TREK K2P channels and highlight the different ways in which filter gating can be regulated to permit polymodal regulation.

Identifiants

pubmed: 34032848
pii: 212184
doi: 10.1085/jgp.202012812
pmc: PMC8155809
pii:
doi:

Substances chimiques

Potassium Channels, Tandem Pore Domain 0
Fluoxetine 01K63SUP8D
norfluoxetine K8D70XE2F4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S008608/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N000145/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/T002018/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 109114/Z/15/A
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT084655MA
Pays : United Kingdom

Informations de copyright

© 2021 Proks et al.

Références

J Am Chem Soc. 2004 Nov 17;126(45):14694-5
pubmed: 15535674
Science. 2012 Jan 27;335(6067):436-41
pubmed: 22282805
Nature. 2014 Dec 4;516(7529):126-30
pubmed: 25471887
Science. 2015 Mar 13;347(6227):1256-9
pubmed: 25766236
Science. 2012 Jan 27;335(6067):432-6
pubmed: 22282804
J Gen Physiol. 2019 Mar 4;151(3):342-356
pubmed: 30796095
Cell. 2016 Feb 25;164(5):937-49
pubmed: 26919430
J Physiol. 2007 Aug 15;583(Pt 1):57-69
pubmed: 17540699
EMBO J. 2011 Aug 05;30(17):3607-19
pubmed: 21822218
Neuroscience. 2015 Aug 6;300:85-93
pubmed: 25982558
J Gen Physiol. 2016 Jun;147(6):497-505
pubmed: 27241700
Pharmacol Ther. 2019 Feb;194:185-198
pubmed: 30291907
J Physiol. 1985 Dec;369:501-57
pubmed: 2419552
J Physiol. 2008 Dec 1;586(23):5651-63
pubmed: 18845607
J Med Chem. 2016 Jun 9;59(11):5149-57
pubmed: 26588045
J Gen Physiol. 1971 Oct;58(4):413-37
pubmed: 5112659
Physiol Rev. 2010 Apr;90(2):559-605
pubmed: 20393194
Nat Neurosci. 2006 Sep;9(9):1134-41
pubmed: 16906152
J Gen Physiol. 2009 Aug;134(2):151-64
pubmed: 19635856
EMBO J. 2011 Jul 15;30(17):3594-606
pubmed: 21765396
Pflugers Arch. 2015 May;467(5):931-43
pubmed: 25420526
Structure. 2017 May 2;25(5):708-718.e2
pubmed: 28392258
Sci Adv. 2020 Oct 30;6(44):
pubmed: 33127683
Mol Pharmacol. 2016 Sep;90(3):309-17
pubmed: 27268784
Protein Sci. 2018 Jan;27(1):112-128
pubmed: 28836357
Front Mol Neurosci. 2018 Sep 04;11:301
pubmed: 30233308
Neuron. 2001 Nov 20;32(4):635-48
pubmed: 11719204
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8343-E8351
pubmed: 28923939
J Gen Physiol. 1984 Aug;84(2):157-86
pubmed: 6092514
J Physiol. 1992 Jan;445:549-68
pubmed: 1501145
Br J Pharmacol. 2005 Mar;144(6):821-9
pubmed: 15685212
Front Pharmacol. 2019 Apr 11;10:379
pubmed: 31031627
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41
pubmed: 11517324
Sci Rep. 2016 Feb 16;6:21248
pubmed: 26879043
Channels (Austin). 2012 Nov-Dec;6(6):473-8
pubmed: 22991046
Science. 1996 Feb 2;271(5249):653-6
pubmed: 8571129
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):E1713-22
pubmed: 24733889
Gen Physiol Biophys. 2013 Jun;32(2):189-200
pubmed: 23479450
Neuron. 2014 Dec 17;84(6):1198-212
pubmed: 25500157
Nature. 2020 Jun;582(7812):443-447
pubmed: 32499642
Science. 2019 Feb 22;363(6429):875-880
pubmed: 30792303
Nat Struct Mol Biol. 2013 Feb;20(2):159-66
pubmed: 23262489
Nature. 2020 Oct;586(7829):457-462
pubmed: 32999458
Nature. 2017 Jul 20;547(7663):364-368
pubmed: 28693035
J Biol Chem. 2020 Jan 10;295(2):610-618
pubmed: 31806709

Auteurs

Peter Proks (P)

Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK.
OXION Initiative in Ion Channels and Disease, University of Oxford, Oxford, UK.

Marcus Schewe (M)

Department of Physiology, University of Kiel, Kiel, Germany.

Linus J Conrad (LJ)

Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK.
OXION Initiative in Ion Channels and Disease, University of Oxford, Oxford, UK.

Shanlin Rao (S)

Department of Biochemistry, University of Oxford, Oxford, UK.

Kristin Rathje (K)

Department of Physiology, University of Kiel, Kiel, Germany.

Karin E J Rödström (KEJ)

Centre for Medicines Discovery, University of Oxford, UK.

Elisabeth P Carpenter (EP)

OXION Initiative in Ion Channels and Disease, University of Oxford, Oxford, UK.
Centre for Medicines Discovery, University of Oxford, UK.

Thomas Baukrowitz (T)

Department of Physiology, University of Kiel, Kiel, Germany.

Stephen J Tucker (SJ)

Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK.
OXION Initiative in Ion Channels and Disease, University of Oxford, Oxford, UK.

Articles similaires

Adenosine Triphosphate Adenosine Diphosphate Mitochondrial ADP, ATP Translocases Binding Sites Mitochondria

Conservation of the cooling agent binding pocket within the TRPM subfamily.

Kate Huffer, Matthew C S Denley, Elisabeth V Oskoui et al.
1.00
TRPM Cation Channels Animals Binding Sites Mice Pyrimidinones
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics

Amyloid accelerator polyphosphate fits as the mystery density in α-synuclein fibrils.

Philipp Huettemann, Pavithra Mahadevan, Justine Lempart et al.
1.00
Polyphosphates alpha-Synuclein Humans Amyloid Molecular Dynamics Simulation

Classifications MeSH